메뉴 건너뛰기




Volumn 21, Issue SUPPL.1, 2010, Pages

Breast cancer: Complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma

Author keywords

Cardiac toxicity; Hypotiroidism; Metastatic breast cancer; Sunitinib; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; LEVOTHYROXINE; SUNITINIB; TRASTUZUMAB;

EID: 76449117174     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000361532.36428.42     Document Type: Article
Times cited : (4)

References (7)
  • 1
    • 76449094956 scopus 로고    scopus 로고
    • Phase II trial of sunitinib in patients with previously-treated metastatic breast cancer
    • Abstract 563 oral presentation
    • Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MD, Pegram MD, et al. Phase II trial of sunitinib in patients with previously-treated metastatic breast cancer. ASCO 2005; (Abstract 563, oral presentation).
    • (2005) ASCO
    • Miller, K.D.1    Burstein, H.J.2    Elias, A.D.3    Rugo, H.S.4    Cobleigh, M.D.5    Pegram, M.D.6
  • 2
    • 2442669093 scopus 로고    scopus 로고
    • Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer
    • Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2:1011-1021.
    • (2003) Mol Cancer Ther , vol.2 , pp. 1011-1021
    • Abrams, T.J.1    Murray, L.J.2    Pesenti, E.3    Holway, V.W.4    Colombo, T.5    Lee, L.B.6
  • 3
    • 33749505836 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
    • Demetri GD, van Oosterom AT, Garret CR, Blackstein M, Shah M, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-1338.
    • (2006) Lancet , vol.368 , pp. 1329-1338
    • Demetri, G.D.1    Van Oosterom, A.T.2    Garret, C.R.3    Blackstein, M.4    Shah, M.5    Verweij, J.6
  • 5
    • 9144274970 scopus 로고    scopus 로고
    • SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in a experimental breast cancer bone metastasis model
    • Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in a experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20:757-766.
    • (2003) Clin Exp Metastasis , vol.20 , pp. 757-766
    • Murray, L.J.1    Abrams, T.J.2    Long, K.R.3    Ngai, T.J.4    Olson, L.M.5    Hong, W.6
  • 6
    • 33947504730 scopus 로고    scopus 로고
    • Sunitinib: From rational design to clinical efficacy
    • Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25:884-896.
    • (2007) J Clin Oncol , vol.25 , pp. 884-896
    • Chow, L.Q.1    Eckhardt, S.G.2
  • 7
    • 33644847440 scopus 로고    scopus 로고
    • Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    • Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25-35.
    • (2006) J Clin Oncol , vol.24 , pp. 25-35
    • Faivre, S.1    Delbaldo, C.2    Vera, K.3    Robert, C.4    Lozahic, S.5    Lassau, N.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.